U.S. markets closed

Soligenix, Inc. (SNGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6300-0.0200 (-1.21%)
At close: 4:00PM EST

1.6500 +0.02 (1.23%)
After hours: 6:34PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.6500
Open1.6974
Bid1.6300 x 900
Ask1.6500 x 1100
Day's Range1.6200 - 1.7200
52 Week Range1.2100 - 3.2000
Volume1,387,408
Avg. Volume3,981,358
Market Cap51.321M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.5960
Earnings DateMar 29, 2021 - Apr 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
    PR Newswire

    Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.

  • Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
    Newsfile

    Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track

    New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SNGX) is fast approaching a new drug application (NDA) submission and potential FDA approval for SGX301 (synthetic hypericin), a photodynamic treatment option to battle the debilitating effects of cutaneous T-Cell lymphoma (CTCL).The most recent treatment option in their rare disease pipeline, SGX301, will ...

  • Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference
    PR Newswire

    Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Digital Conference taking place February 16-18, 2021. The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:00 AM EST via the virtual conference link. Alternatively, an audio webcast of the Soligenix corporate presentation is available on the Company's website via this link.